Alexandra U Scherrer
Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients
Metzner K, Günthard H, Weber R, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Hirsch H, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, von Wyl V, Scherrer A, the Swiss HIV Cohort Study. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. AIDS 2014; 28:2231-2239.
24.09.2014Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients
24.09.2014AIDS 2014; 28:2231-2239
Metzner Karin J, Günthard Huldrych F, Weber Rainer, Bernasconi Enos, Calmy Alexandra, Cavassini Matthias, Vernazza Pietro, Hirsch Hans H, Furrer Hansjakob, Aubert Vincent, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Scherrer Alexandra U, the Swiss HIV Cohort Study
Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, the Swiss HIV Cohort Study (SHCS). Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. PloS one 2013; 8
25.07.2013Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
25.07.2013PloS one 2013; 8
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Aubert Vincent, Klimkait Thomas, Yerly Sabine, Böni Jürg, the Swiss HIV Cohort Study (SHCS)
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
Metzner K, Aubert V, Furrer H, Battegay M, Vernazza P, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard H, Klimkait T, Yerly S, Böni J, Scherrer A, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Swiss HIV Cohort Study. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis 2013; 208:1102-12.
11.07.2013Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
11.07.2013J Infect Dis 2013; 208:1102-12
Metzner Karin J, Aubert Vincent, Furrer Hansjakob, Battegay Manuel, Vernazza Pietro, Cavassini Matthias, Calmy Alexandra, Bernasconi Enos, Weber Rainer, Günthard Huldrych F, Klimkait Thomas, Yerly Sabine, Böni Jürg, Scherrer Alexandra U, Preiswerk Benjamin, Joos Beda, von Wyl Viktor, Leemann Christine, Rieder Philip, Braun Dominique, Grube Christina, Kuster Herbert, Swiss HIV Cohort Study
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. PloS one 2012; 7:e50307.
26.11.2012Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
26.11.2012PloS one 2012; 7:e50307
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Aubert Vincent, Klimkait Thomas, Yerly Sabine, Böni Jürg, Swiss HIV Cohort Study (SHCS)
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Cellerai C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PloS one 2012; 7:e37983.
18.06.2012Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
18.06.2012PloS one 2012; 7:e37983
Scherrer Alexandra U, Günthard Huldrych F, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Calmy Alexandra, Furrer Hansjakob, Cellerai Cristina, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Ledergerber Bruno, Swiss HIV Cohort Study
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B
Scherrer A, Günthard H, Held L, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Hirschel B, Rauch A, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011; 53:1143-52.
13.10.2011Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B
13.10.2011Clin Infect Dis 2011; 53:1143-52
Scherrer Alexandra U, Günthard Huldrych F, Held Leonhard, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Hirschel Bernard, Rauch Andri, Bürgisser Philippe, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Ledergerber Bruno, Swiss HIV Cohort Study
Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Hirschel B, Garzoni C, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Swiss HIV Cohort Study (SHCS). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2011; 57:24-31.
01.05.2011Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
01.05.2011J Acquir Immune Defic Syndr 2011; 57:24-31
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Cavassini Matthias, Hirschel Bernard, Garzoni Christian, Bürgisser Philippe, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Swiss HIV Cohort Study (SHCS)